Abstract
CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.
Translated title of the contribution | C-reactive protein as a novel biomarker |
---|---|
Original language | Undefined/Unknown |
Pages (from-to) | 33-38 |
Number of pages | 6 |
Journal | SENDROM |
Volume | 16 |
Issue number | 12 |
State | Published - Dec 2004 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)